Spreadsheet: 95655aac-d31b-4c71-acde-b7e8077c1a44
Sheet: tab18

 |  | Estimated Vaccination Coverage*,† with Selected Vaccines Among Adolescents 13-17 Years of Age§ by Poverty Level¶ and Race/Ethnicity**  -- National Immunization Survey-Teen, United States, 2012
Vaccines |  | Total | White only,                        non-Hispanic | Black only,                         non-Hispanic | Hispanic | American Indian or [NAME] only, non-Hispanic | Asian only, non-Hispanic
 |  | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.)
≥2 MMR†† | US National | 91.4(±0.8) | 92.4(±0.8) | 91.4(±2.3) | 89.1(±2.2) | 95.9(±4.2) | 90.4(±4.6)
 | At or Above Poverty | 92.0(±0.8) | 92.8(±0.9) | 91.5(±3.0) | 90.2(±2.5) | 96.6(±3.7) | 89.0(±5.8)
 | Below Poverty | 89.7(±1.9) | 89.9(±2.5) | 91.0(±3.7) | 87.7(±3.7) | 99.0(±1.6) | 93.3(±8.0)
 | Unknown Poverty | 92.3(±3.0) | 93.2(±3.6) | 92.1(±7.7) | 92.3(±6.9) | NA | NA
[NAME] 3 [NAME] | US National | 92.8(±0.7) | 93.7(±0.7) | 92.5(±2.1) | 91.1(±2.1) | 94.1(±5.8) | 92.0(±3.8)
 | At or Above Poverty | 93.3(±0.8) | 94.0(±0.7) | 93.1(±2.9) | 91.0(±2.9) | 97.4(±3.5) | 93.5(±4.0)
 | Below Poverty | 91.3(±1.7) | 91.7(±2.4) | 91.6(±3.5) | 91.1(±3.2) | 92.9(±11.6) | 87.6(±10.1)
 | Unknown Poverty | 93.3(±2.8) | 94.8(±3.4) | 92.4(±7.0) | 92.6(±6.7) | NA | NA
[NAME] 1 Var¶¶ | US National | 94.7(±0.8) | 95.3(±0.8) | 93.3(±2.5) | 94.1(±2.1) | 95.2(±6.9) | 93.5(±4.4)
 | At or Above Poverty | 95.3(±0.8) | 95.7(±0.8) | 93.3(±3.4) | 95.7(±2.0) | 99.5(±0.6) | 92.0(±5.8)
 | Below Poverty | 92.5(±2.0) | 91.9(±2.9) | 93.1(±4.0) | 92.1(±3.9) | 87.6(±17.9) | 97.3(±4.6)
 | Unknown Poverty | 97.1(±1.9) | 97.9(±1.6) | 94.5(±7.6) | 99.0(±1.5) | NA | NA
[NAME]*** | US National | 74.9(±1.4) | 74.0(±1.7) | 75.2(±3.9) | 76.3(±3.5) | 78.4(±11.8) | 79.4(±8.0)
 | At or Above Poverty | 75.8(±1.5) | 75.6(±1.7) | 76.5(±4.8) | 76.2(±4.8) | 74.7(±16.2) | 77.9(±8.6)
 | Below Poverty | 72.0(±3.3) | 61.8(±5.8) | 71.7(±7.1) | 76.8(±5.3) | 79.3(±21.0) | 84.6(±20.5)
 | Unknown Poverty | 77.9(±6.2) | 77.8(±7.9) | 85.7(±11.1) | 72.5(±17.4) | NA | NA
[NAME] 1 Td or Tdap††† | US National | 88.5(±0.8) | 87.9(±0.9) | 87.7(±2.2) | 89.6(±2.3) | 93.8(±3.8) | 92.8(±3.6)
 | At or Above Poverty | 88.6(±0.9) | 88.3(±1.0) | 87.6(±2.9) | 90.0(±3.3) | 90.7(±6.5) | 91.2(±5.0)
 | Below Poverty | 88.1(±1.8) | 84.9(±3.1) | 87.5(±3.6) | 89.3(±3.3) | 97.3(±2.7) | 99.0(±1.2)
 | Unknown Poverty | 89.6(±3.6) | 90.4(±4.0) | 89.7(±8.1) | 88.1(±10.7) | NA | NA
[NAME] 1 Tdap§§§ | US National | 84.6(±0.9) | 84.4(±1.0) | 83.7(±2.5) | 85.4(±2.5) | 89.5(±5.6) | 84.9(±5.4)
 | At or Above Poverty | 85.1(±1.0) | 85.0(±1.1) | 84.0(±3.3) | 86.8(±3.5) | 89.4(±6.9) | 83.6(±6.7)
 | Below Poverty | 83.6(±2.1) | 80.7(±3.5) | 84.1(±3.9) | 84.1(±3.9) | 92.6(±5.6) | 93.8(±4.5)
 | Unknown Poverty | 82.8(±5.1) | 85.4(±5.0) | 78.4(±16.4) | 85.1(±11.1) | NA | NA
[NAME] 1 MenACWY¶¶¶ | US National | 74.0(±1.1) | 71.3(±1.3) | 75.8(±3.2) | 77.6(±3.2) | 82.0(±7.9) | 79.4(±6.4)
 | At or Above Poverty | 74.1(±1.3) | 72.5(±1.4) | 76.6(±4.0) | 76.4(±4.2) | 82.1(±9.8) | 78.3(±6.9)
 | Below Poverty | 73.2(±2.7) | 63.2(±4.2) | 75.3(±5.2) | 78.3(±5.0) | 84.3(±12.7) | 80.4(±16.0)
 | Unknown Poverty | 77.1(±5.4) | 76.5(±6.2) | 70.8(±17.7) | 82.1(±12.4) | NA | NA
FEMALE
[NAME] 1 HPV**** | US National | 53.8(±1.9) | 51.1(±2.1) | 50.1(±5.4) | 62.9(±4.9) | 67.7(±15.5) | 55.9(±10.9)
 | At or Above Poverty | 50.4(±2.0) | 50.6(±2.3) | 46.2(±6.8) | 52.2(±6.6) | 62.5(±25.5) | 52.6(±11.3)
 | Below Poverty | 64.9(±4.2) | 56.2(±6.3) | 59.9(±9.0) | 73.9(±7.1) | 75.5(±20.3) | 61.4(±27.3)
 | Unknown Poverty | 42.0(±9.4) | 41.7(±10.8) | NA | 52.1(±24.1) | NA | NA
[NAME] 2 HPV†††† | US National | 43.4(±1.9) | 41.8(±2.1) | 39.5(±5.1) | 49.3(±5.1) | 43.2(±17.7) | 48.1(±11.1)
 | At or Above Poverty | 40.7(±2.0) | 41.9(±2.2) | 36.7(±6.5) | 39.7(±6.4) | NA | 41.8(±11.1)
 | Below Poverty | 51.5(±4.4) | 42.6(±6.2) | 46.0(±8.8) | 59.2(±8.1) | 56.6(±23.2) | 60.7(±27.3)
 | Unknown Poverty | 35.9(±9.0) | 36.3(±10.5) | NA | 38.8(±21.9) | NA | NA
[NAME] 3 HPV§§§§ | US National | 33.4(±1.7) | 33.7(±2.0) | 29.0(±4.7) | 35.5(±4.8) | 36.8(±16.5) | 33.8(±10.2)
 | At or Above Poverty | 32.5(±1.9) | 34.3(±2.2) | 26.4(±6.0) | 30.3(±6.1) | NA | 32.8(±10.6)
 | Below Poverty | 36.2(±4.2) | 30.8(±5.7) | 33.8(±8.1) | 40.9(±7.8) | 50.8(±23.2) | NA
 | Unknown Poverty | 31.0(±8.7) | 31.1(±10.1) | NA | NA | NA | NA
HPV 3 dose series completion¶¶¶¶ | US National | 66.7(±2.6) | 71.8(±2.7) | 63.7(±7.1) | 59.3(±6.8) | 55.4(±27.4) | 61.8(±15.8)
 | At or Above Poverty | 69.9(±2.7) | 73.5(±2.8) | 62.7(±10.1) | 63.3(±8.9) | NA | 64.4(±16.3)
 | Below Poverty | 59.3(±5.8) | 61.1(±8.6) | 62.7(±10.7) | 56.7(±9.8) | 68.3(±25.0) | NA
 | Unknown Poverty | 76.0(±11.0) | 76.3(±13.4) | NA | NA | NA | NA
MALE
[NAME] 1 HPV**** | US National | 20.8(±1.5) | 15.2(±1.4) | 25.9(±4.6) | 31.7(±4.7) | 24.9(±12.0) | 22.3(±8.7)
 | At or Above Poverty | 17.3(±1.5) | 14.5(±1.4) | 22.9(±5.5) | 23.5(±5.6) | 27.0(±15.4) | 19.2(±9.0)
 | Below Poverty | 29.9(±3.9) | 18.1(±4.5) | 29.9(±8.3) | 39.8(±7.4) | NA | NA
 | Unknown Poverty | 26.8(±9.6) | 19.0(±9.5) | NA | NA | NA | NA
[NAME] 2 HPV†††† | US National | 12.7(±1.3) | 9.0(±1.1) | 15.6(±3.8) | 20.1(±4.1) | NA | 17.1(±7.8)
 | At or Above Poverty | 10.2(±1.2) | 8.9(±1.2) | 11.8(±3.6) | 13.5(±4.4) | NA | 15.2(±8.6)
 | Below Poverty | 18.8(±3.4) | 8.3(±3.0) | 21.0(±8.0) | 25.7(±6.7) | NA | NA
 | Unknown Poverty | 18.5(±9.0) | NA | NA | NA | NA | NA
[NAME] 3 HPV§§§§ | US National | 6.8(±1.0) | 4.6(±0.8) | 5.4(±1.9) | 12.9(±3.5) | NA | NA
 | At or Above Poverty | 5.5(±0.9) | 4.4(±0.8) | 6.2(±2.8) | 7.6(±3.2) | NA | NA
 | Below Poverty | 10.7(±2.9) | 5.2(±2.6) | NA | 19.1(±6.4) | NA | NA
 | Unknown Poverty | NA | NA | NA | NA | NA | NA
HPV 3 dose series completion¶¶¶¶ | US National | 45.1(±5.0) | 45.2(±6.2) | 27.8(±9.2) | 52.1(±10.3) | NA | 62.7(±23.6)
 | At or Above Poverty | 47.2(±5.6) | 46.5(±6.8) | 40.0(±14.3) | 47.6(±14.4) | NA | 81.3(±16.2)
 | Below Poverty | 43.6(±9.1) | 38.7(±15.7) | NA | 57.4(±13.3) | NA | NA
 | Unknown Poverty | NA | NA | NA | NA | NA | NA
 |  | *  Estimate presented as point estimate (%) ± 95% confidence interval (CI). Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588.
 |  | † Estimates with confidence intervals >20 may not be reliable.
 |  | § Adolescents in the 2012 NIS-Teen were born during January 1994-February 2000. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in the U.S. Virgin Islands (i.e., St. Croix, St. Thomas, St. John, and Water Island)(n=547: 262 females and 285 males).
 |  | ¶ Poverty status was based on 2011 U.S. Census poverty thresholds (available at http://www.census.gov/hhes/www/poverty/data/threshld/index.html).
 |  | ** Reported by respondent. Adolescents identified as White, Black, American Indian/Alaska Native, or Asian. Native Hawaiian/Pacific Islanderand persons of multiple races were not included because of small sample sizes. Adolescents of Hispanic ethnicity may be of any race.
 |  | ††  [NAME] 2 doses of measles-mumps-rubella vaccine
 |  | §§    ≥3 doses of hepatitis B vaccine.
 |  | ¶¶    [NAME] 1 dose of varicella vaccine among adolescents without a history of varicella disease.
 |  | ***   [NAME] 2 doses of varicella vaccine among adolescents without a history of varicella disease.
 |  | [NAME] 1 dose of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years.
 |  | §§§ ≥ 1 dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years.
 |  | ¶¶¶   ≥1  dose of meningococcal conjugate vaccine or meningococcal -unknown type vaccine.
 |  | ****   ≥1 dose of human papillomavirus vaccine, either quadrivalent or bivalent. Percentages reported among females  only (N=9,058) and among males only(N=10,141)
 |  | †††† ≥2 doses of human papillomavirus vaccine, either quadrivalent or bivalent.
 |  | §§§§ ≥3 doses of human papillomavirus vaccine, either quadrivalent or bivalent. Some adolescents may have received more than the three recommended HPV doses.
 |  | ¶¶¶¶  Percent of females and males who received three doses among those who had at least one HPV dose and at least 24 weeks between the first dose and the interview date.